earli phas clinic trial rais enthusiasm insulinlik growth factor receptor igfrspecif antibodi cancer treatment initi phas iii result unselect patient disappoint clinic studi benefit predict biomark identifi respond ration combin therapi consider altern target strategi ligandspecif antibodi receptorspecif tyrosin kinas inhibitor target insulin igf signall broader context pathophysiologi relat obes diabet neoplasia effect antidiabet drug includ metformin cancer risk prognosi insulin igfi receptor famili relev develop pikakt pathwai inhibitor 
